MNKD – MannKind Corporation
MNKD — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.26
Margin Of Safety %
Put/Call OI Ratio
0.13
EPS Next Q Diff
0.14
EPS Last/This Y
0.08
EPS This/Next Y
0.12
Price
4.1
Target Price
7.97
Analyst Recom
1.25
Performance Q
15.77
Upside
-219.2%
Beta
1.09
Ticker: MNKD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | MNKD | 4.03 | 0.16 | 0.01 | 74563 |
| 2026-07-14 | MNKD | 3.88 | 0.16 | 0.02 | 76901 |
| 2026-07-15 | MNKD | 4.09 | 0.15 | 0.01 | 79699 |
| 2026-07-16 | MNKD | 4.05 | 0.15 | 0.02 | 81887 |
| 2026-07-17 | MNKD | 4.03 | 0.15 | 0.01 | 79468 |
| 2026-07-20 | MNKD | 3.98 | 0.15 | 0.01 | 78495 |
| 2026-07-21 | MNKD | 4.05 | 0.14 | 0.05 | 82391 |
| 2026-07-22 | MNKD | 3.84 | 0.14 | 0.02 | 84724 |
| 2026-07-23 | MNKD | 3.89 | 0.13 | 0.08 | 87893 |
| 2026-07-24 | MNKD | 4.14 | 0.13 | 0.02 | 89694 |
| 2026-07-27 | MNKD | 3.95 | 0.13 | 0.07 | 89413 |
| 2026-07-28 | MNKD | 3.91 | 0.13 | 0.15 | 90664 |
| 2026-07-29 | MNKD | 3.85 | 0.13 | 0.01 | 91866 |
| 2026-07-30 | MNKD | 4.12 | 0.13 | 0.06 | 92893 |
| 2026-07-31 | MNKD | 3.92 | 0.13 | 0.10 | 93168 |
| 2026-08-03 | MNKD | 3.81 | 0.13 | 0.04 | 89807 |
| 2026-08-04 | MNKD | 3.97 | 0.13 | 0.04 | 91608 |
| 2026-08-05 | MNKD | 4.04 | 0.13 | 0.10 | 92808 |
| 2026-08-06 | MNKD | 3.88 | 0.13 | 0.27 | 93939 |
| 2026-08-07 | MNKD | 4.11 | 0.13 | 0.09 | 95120 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | MNKD | 4.03 | -75.0 | - | 0.09 |
| 2026-07-14 | MNKD | 3.88 | -75.0 | - | 0.09 |
| 2026-07-15 | MNKD | 4.10 | -75.0 | - | 0.09 |
| 2026-07-16 | MNKD | 4.05 | -75.0 | - | 0.09 |
| 2026-07-17 | MNKD | 4.03 | -75.0 | - | 0.09 |
| 2026-07-20 | MNKD | 3.98 | -75.0 | - | 0.09 |
| 2026-07-21 | MNKD | 4.05 | -75.0 | - | 0.09 |
| 2026-07-22 | MNKD | 3.84 | -75.0 | - | 0.09 |
| 2026-07-23 | MNKD | 3.89 | -75.0 | - | 0.09 |
| 2026-07-24 | MNKD | 4.14 | -75.0 | - | 0.09 |
| 2026-07-27 | MNKD | 3.95 | -75.0 | - | 0.09 |
| 2026-07-28 | MNKD | 3.91 | -75.0 | - | 0.09 |
| 2026-07-29 | MNKD | 3.85 | -75.0 | - | 0.09 |
| 2026-07-30 | MNKD | 4.12 | -75.0 | - | 0.09 |
| 2026-07-31 | MNKD | 3.92 | -65.0 | - | 0.10 |
| 2026-08-03 | MNKD | 3.81 | -65.0 | - | 0.10 |
| 2026-08-04 | MNKD | 3.81 | -65.0 | - | 0.10 |
| 2026-08-05 | MNKD | 4.12 | -65.0 | - | 0.10 |
| 2026-08-06 | MNKD | 3.88 | -65.0 | - | 0.10 |
| 2026-08-07 | MNKD | 4.10 | -64.3 | - | 0.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | MNKD | 0.56 | -1.62 | 8.89 |
| 2026-07-14 | MNKD | 0.56 | -1.62 | 8.89 |
| 2026-07-15 | MNKD | 0.56 | -1.62 | 8.89 |
| 2026-07-16 | MNKD | 0.56 | -1.62 | 8.89 |
| 2026-07-17 | MNKD | 0.56 | -1.62 | 8.89 |
| 2026-07-20 | MNKD | 0.02 | -1.53 | 8.89 |
| 2026-07-21 | MNKD | 0.02 | -1.53 | 8.89 |
| 2026-07-22 | MNKD | 0.02 | -1.53 | 8.89 |
| 2026-07-23 | MNKD | 0.02 | -1.53 | 8.89 |
| 2026-07-24 | MNKD | 0.02 | -1.53 | 8.89 |
| 2026-07-27 | MNKD | 0.02 | -1.34 | 9.57 |
| 2026-07-28 | MNKD | 0.02 | -1.34 | 9.57 |
| 2026-07-29 | MNKD | 0.02 | -1.34 | 9.57 |
| 2026-07-30 | MNKD | 0.02 | -1.34 | 9.57 |
| 2026-07-31 | MNKD | 0.02 | -1.34 | 9.26 |
| 2026-08-03 | MNKD | 0.02 | -1.58 | 9.26 |
| 2026-08-04 | MNKD | 0.02 | -1.58 | 9.26 |
| 2026-08-05 | MNKD | 0.02 | -1.58 | 9.26 |
| 2026-08-06 | MNKD | 0.02 | -1.58 | 9.26 |
| 2026-08-07 | MNKD | 0.02 | -1.58 | 9.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
0.03
Avg. EPS Est. Next Quarter
0.08
Insider Transactions
0.02
Institutional Transactions
-1.58
Beta
1.09
Average Sales Estimate Current Quarter
120
Average Sales Estimate Next Quarter
143
Fair Value
Quality Score
47
Growth Score
62
Sentiment Score
32
Actual DrawDown %
46.3
Max Drawdown 5-Year %
-69.4
Target Price
7.97
P/E
Forward P/E
PEG
P/S
3.36
P/B
P/Free Cash Flow
EPS
-0.14
Average EPS Est. Cur. Y
0.1
EPS Next Y. (Est.)
0.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-11.08
Relative Volume
0.91
Return on Equity vs Sector %
37.6
Return on Equity vs Industry %
53.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
◆
MNKD
Healthcare
$4.11
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
53.9
Range 1M
66.7%
Sup Dist
9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-1006.3%
EPS NY
100%
52W%
43.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+89.2% upside
Upside
+89.2%
Quality
47
MNKD — P/E HistoricalBiotechnology
MannKind CorporationSector: Healthcare
Industry: Biotechnology
Employees: 591
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MNKD
Latest News
—
Caricamento notizie per MNKD…
stock quote shares MNKD – MannKind Corporation Stock Price stock today
news today MNKD – MannKind Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch MNKD – MannKind Corporation yahoo finance google finance
stock history MNKD – MannKind Corporation invest stock market
stock prices MNKD premarket after hours
ticker MNKD fair value insiders trading